Hi, everyone. My name is Maury Raycroft, and I am one of the Biotech Analysts at Jefferies. I would like to welcome the CRISPR Therapeutics team. We have Sam Kulkarni, the CEO, and Naimish Patel, the CMO. Thanks so much for joining us today. We are going to do fireside chat format, so maybe for those who are new to the story, if you can give a one-minute intro to CRISPR.
Yeah. Thank you, Maury, for having us. It is always fun to be at this conference. We have had an incredible year in 2026 for CRISPR and are poised for even better pipeline and portfolio progression in 2027. What we have is a business that you can categorize into three parts. We have CASGEVY, which is our commercial product, which is getting a lot of momentum, and we will talk more about that. This is in partnership with Vertex, and we believe this could be a multi-billion dollar opportunity. We have our later-stage clinical products, and these are namely CTX310, which is for ANGPTL3 and reduction of triglycerides. We have zugo-cel, which is an allogeneic CAR T, and we have CTX611, which is an siRNA targeted towards Factor XI. Those could all be potentially in late-stage trials within a year or so.
That is actually incredible progress for three programs that could be best in class, and also first in class. Then we have a number of other things in the pipeline which are also very exciting. We have alpha-1 antitrypsin, where we are in the clinic. We have CTX340, which is targeted towards refractory hypertension, and a number of other earlier programs like type 1 diabetes, which will go into the clinic, not too distant future, in vivo CAR T, in vivo HSC editing, et cetera. So, all in all, a very rich pipeline, and we are quite excited about each of these parts, about CASGEVY, we are excited about the programs that are going into late-stage trials, and also the programs that are in earlier development.
Got it. Yeah, it is a great intro, and you have had a couple data updates recently, including the data at AHA. So let us start there with CTX310. You showed some sHTG data with 63% mean triglyceride reduction at day 30, alongside reductions in LDL and ApoB, despite this being a high-risk, all diabetic population. How should we contextualize that profile versus what we have seen with APOC3 agents, and where could ANGPTL3 targeting offer a meaningful advantage?
Yeah, thank you for the question. I'll start, and then I'll hand it over to Naimish to talk to some of the nuances. This is a very exciting dataset. CTX310, for those who are new to the story, targets ANGPTL3, which actually acts on lipoprotein lipase and endothelial lipase, which then act on cholesterol. Long story short, we're putting a check on the brakes that are ANGPTL3, and by reducing ANGPTL3, you effectively unleash the lipoprotein lipases that then chew up the bad cholesterol, right? This is a one-time procedure where you're sitting in a chair for two and a half to three hours, one infusion, and then you're done for life. It's a very attractive proposition, generally, and this is a theme we've been following by one and done for lipid management and cardiovascular risk reduction.
As for the data we just presented at AHA, it was an incredible late breaker presentation, and Naimish, maybe you can talk through some of the data that we presented.
Yeah, absolutely. Just one more background item. The gene itself, ANGPTL3, was identified as a gene that's already naturally occurring mutations, originally in this Italian village where there's a high rate of loss of function mutations, ANGPTL3. The patients who have that tend to have very low LDL, very low triglycerides, and low cardiovascular risk. This has been seen in multiple other populations, sort of that relationship as well. All we're trying to do is recapitulate that mutation with our drug. Our initial data last year at AHA, published in the New England Journal, showed that with a single dose, we could not only produce potent reductions in LDL and triglycerides, but those were durable out to a year. Truly, a single dose can cause a lifetime, potentially, of reduction in lipids.
This is transformational for lipid reduction, because the biggest barrier to patients' control today is compliance with medicines. Our more recent AHA data was in severe hypertriglyceridemia. We had a mean reduction, as you mentioned, close to 65%, which is essentially on par with the APOC3 olezarsen or the siRNA. Every company presents their data a little bit different, mean versus median, but in terms of the effect size, it's there. What we've also shown with that data is eight of 10 patients got below 500, which is the key metric for basically getting rid of the pancreatitis risk associated with triglycerides. The other differentiation points are lowering of atherogenic lipids, which is also very differentiated from the other mechanisms, as the only mechanism that does that.
Got it. Yeah, makes sense. These patients, they start with quite high baseline triglycerides relative to other studies. Beyond the mean percent reduction, what proportion of patients do you expect to achieve normal or near normal triglyceride levels?
Yeah. So basically, as I just mentioned, eight of 10 patients, even at day 28, and we've seen responses deepen over time. Even early data, almost every patient we've treated, we've removed their pancreatitis risk, and that's really the first point that you're looking for treating these patients. The other thing is, these patients are at high risk for cardiovascular outcomes, and it's unclear if just targeting APOC3 will do that, because the LDL seems to increase in some patients, where here, we saw a reduction in LDL, APOC3, and non-HDL cholesterol, all key differentiation points and all associated with atherogenic risk.
Got it. That could potentially differentiate you versus the APOC3 agents.
Absolutely. A couple of other things. We'll have more data on glucose control. Genetic studies suggest knocking down ANGPTL3 actually increases insulin resistance, or decreases insulin resistance, which is a positive, as well as hepatic fat that we don't have the data on yet, but we hope to report upon in the coming year.
Got it. There was the one patient who is a non-responder. Any color on that patient's baseline characteristics or what may have driven the lack of response?
Yeah. I mean, I guess for any drug, it's not unusual to see heterogeneity in response. There's nothing specific about that patient we've identified. I can also say that we've dosed, because we have three other cohorts going in this study, patients with just hypercholesterolemia, patients with familial hypercholesterolemia, and also patients with mixed dyslipidemia, and we've been actively enrolling all of those as well, and we've dosed many more patients. We haven't seen any other patients quite like that, so we think it's probably an unusual occurrence. I think the key is looking at the mean reduction, and it's on par with what we need to get.
Got it. Okay. Talk about liver fat, and whether that could be a differentiator versus APOC3. You captured baseline hepatic fat fraction at approximately 20%. Did liver fat actually fall on CTX310, and do you have the MRI-PDFF data on that?
Yeah, I think there's a lot more data to come on CTX310. I'm pretty convinced that ANGPTL3 is a better target than APOC3, for all the reasons that Naimish mentioned around the LDL and ApoB, hepatic fat fraction, glycemic control. I think we'll have more data as we enroll more patients and dose more patients. Don't forget that we'll have phase I-B data for other cohorts as well, whether it's HoFH or mixed dyslipidemias. I think this, combined with the fact that we have RMAT designation for both severe hypertriglyceridemia as well as LDL reduction, put us in a very favorable position to develop this asset, hopefully with a very efficient phase III design.
Got it. For glycemic control, not showing a lot of details on it yet, probably more to come, but are you generally seeing stabilization there on HbA1c?
Yeah, so we haven't seen any signals as far as glucose control. HbA1c tends to take a few months for it to change in patients, so we hope to have that data in the future. As I mentioned, the genetic data suggests that if you knock out ANGPTL3, you actually increase insulin sensitivity. So we predict based upon the genetics that if anything, we might have a favorable response on glucose control.
Got it. Okay. What needs to happen with this program before you can move into a phase III study, and when should we expect to get that regulatory clarity?
Yeah, we haven't put a timeline on it, but usually when you get an RMAT designation from the FDA, you typically move much faster than typical programs. So you'd get a meeting that's an RMAT meeting, and that's potentially where we would discuss what a phase III might look like. I think after that, we'll provide guidance. But our goal right now is to move as fast as we can to a late-stage trial, given the compelling data that we see in the phase I-B, and also the size of the market. I think there's, while there was some disappointment with how quickly the ASO launched in sHTG, I think every market assessment we've done indicates that this can be a very, very big market for severe hypertriglyceridemia. You don't have the risk of cardiovascular outcome studies in the traditional sense.
What you have here is an outcome study based on acute pancreatitis, which is much more sort of, they can put a handicap around based on triglyceride reduction. All in all, I think all this is moving in a relatively fast fashion, and we hope to provide more updates over the coming months.
Got it. As far as the most efficient paths, it seems like you're leaning toward sHTG, but could you also potentially do something in mixed dyslipidemia patients who are inadequate responders to PCSK9 or something like that?
Absolutely. I think severe hypertriglyceridemia is the first place to start. It's the most, in some ways, the most well-trodden path with triglyceride reduction. ANGPTL3 is also built in bispecific in a way. You're getting both triglyceride and LDL reduction off of one target, right? So that actually is very interesting in mixed dyslipidemias. It's also very interesting in homozygous FH because what could happen is, there are patients who are recalcitrant or do not respond to PCSK9s, and ANGPTL3 is a different pathway for LDL reduction that could be synergistic with PCSK9. So all those are possibilities for late-stage trials.
Got it. Where does CTX310 fit in the treatment paradigm versus the chronic RNA or ASO therapies? Given the potentially higher upfront cost of a one-time therapy, what patient profile would make the most sense?
Yeah. I mean, I think the true promise of all these one-and-dones is that our real-world efficacy will always be better than something that requires chronic administration. Although we tend to, as is normal, compare the numbers in the trials, active trials, they will never achieve the same efficacy in the real world as they do in the trial because of all these issues with compliance, insurance changing, all this. We can offer something where payers know exactly what the outcome is going to be. We give a single dose, that will be the reduction in triglycerides, and that will be what patients see for the rest of their lives. There is actually, I think, good incentives for payers to pay for something because they know exactly what they are getting. We anticipate the population for this would be identical to their population.
Well, we probably, in terms of pricing, it will be a discussion on some multiple of the yearly price, but something that our COGS are fairly low. We are able to produce this drug quite efficiently, so we do not need to have super high rare pricing and something competitive that it will be the same drug available to the same patient population.
That makes sense. Yeah. Let's switch gears, talk about zugo-cel, where you just had data at ACR. Maybe talk about the two ongoing phase I trials, and what are three key takeaways from the ACR data update?
Yeah, let me just frame zugo-cel, and then we will talk about the data we presented. Zugo-cel is a best-in-class allogeneic CAR T that is targeted towards CD19, and the reason it is best in class is because we have made edits using CRISPR to make it very potent. What you are getting essentially is an autologous-like efficacy with an allogeneic CAR T, and all the convenience that comes with an allogeneic CAR T, and the safety aspect of it. Recently, there have been reports of deaths in CAR T trials that use autologous CAR Ts, but with allogeneic CAR T, you have no such risk because the cells, after they do their job, disappear, and they are rejected by the patient's body. So you get this great safety profile from a CRS ICANS perspective, but at the same time, because we made these potency edits to the CAR Ts, you are getting autologous-like efficacy.
We will dive more into the data we just presented, but we started basket trials for zugo-cel in a rheum basket, which includes lupus, myositis, and scleroderma. We just presented data for scleroderma and disclosed some data for myositis, albeit a little bit early. The data looked really exciting. Almost every patient has responded, and we will talk more about data. We have also expanded the trials into indications that are neuroimmune, for instance, because allogeneic CAR Ts have the promise of getting into the CNS system, which other CAR Ts may not, whether they are in vivo CAR Ts or transient mRNA-based CAR Ts. Overall, we feel very excited about the program, not to mention the fact that we have our own manufacturing.
We have a cost of goods that is sub $10,000 per patient, and we have tremendous flexibility in terms of scalability to treat and address diseases for all the patients that require and deserve this type of therapy.
Makes sense. As far as just what you are seeing in the scleroderma cohort, do you think the shorter-lived Allo CAR T exposure is sufficient to induce a durable immune response and reset there?
Yeah, I definitely think so. I mean, in some ways, zugo-cel is the ideal situation for autoimmune disease. This translated really, we saw it in our oncology data. We do have a presentation of ASH, of our updated oncology data, and the nexus of this is the two additional edits. What they allow the T-cell to do is expand much more vigorously in the first 28 days, and then the CAR Ts tend to be cleared by the immune response and go away. What we saw in oncology already, several patients with long-lived remissions despite the fact that our CAR T doesn't persist. What that tells us is that you don't need a CAR T that persists a long time. You need a CAR T that is so active that within the window, it can obliterate all the target cells, the B cells, and then go away.
That's the ideal scenario for autoimmune disease because you do not want long-lived CAR Ts to have side effects such as prolonged B-cell aplasia or future malignant risks or anything else. You want that immune reset. That immune reset is probably afforded by a combination of the LD chemo and complete B-cell depletion. We have already seen the early efficacy results as we showed in scleroderma, where six of seven patients had an early CRISS-25 response. What we have seen in scleroderma is the responses tend to deepen over time. The two patients that passed the six-month mark actually had a CRISS-50, our CRISS-50 response. We expect to see good durability and deepening of response as it goes on, but we think the lack of persistence is actually a positive attribute for autoimmune disease.
Got it. As far as lung function goes in these patients, is that something where you want to eventually see benefit there? What magnitude of benefit and timing would you want to see there?
Absolutely. For scleroderma in particular, you definitely want to see a lung function benefit because ultimately, most of these patients, the biggest cause of mortality is the lung disease, interstitial lung disease. Only three of the patients in this cohort actually had interstitial lung disease at baseline. What we have seen with competitor data is that the lung function improvement tends to take a little while, past month six. We are continuing to follow these patients. What we have seen thus far is nobody has had a continued decline. A couple of patients came into the trial rapidly progressing, and they have stabled off. Then we will see after they go past month six, we will be looking for the improvements. But so far, the data is very promising in that regard.
That could be an update sometime next year, potentially, on that front?
Yeah, absolutely.
Okay. For just how you contextualize this program versus FATE, CABA, and ALLO, I guess, do you have room to differentiate there?
Yeah, I think it's early. I think a lot of presentations at ACR and other conferences, and we'll probably see some at ASH, but I do think we're differentiating in the sense that we're getting the same data as autologous players with a much better safety profile, and this convenience and scalability. So, I do think it's very promising with zugo-cel.
Got it.
Maybe one thing just to add that, a couple patients didn't have great expansion, so we've decided to go up a level in dose. We still have room to improve efficacy even further by going up in dose. We're not close to the dose what we're using in oncology yet. It's a little bit challenging because you have to wait for some results in the first dose, but instead of waiting, we're going to go up in the second dose. We have sort of a couple levers to pull in terms of getting optimal efficacy.
Right. Okay. Let's shift gears. We'll talk about Factor XI, which is the siRNA program from Sirius. Is there any more granularity on the status for where the study is and timing for when you could do the phase II update?
Yeah. For those who are new to this program, CTX611, or SRSD107, this is a partner program with a company called Sirius, and this is a best-in-class siRNA. The platform basically is a gen 3 platform. If you think of some siRNA companies that founded the whole space, like Alnylam, there have been several improvements to the platform to make it much more durable, get much deeper target engagement. CTX611 is an example of that. What you could have, as we saw in our phase I studies, is deep depletion of Factor XI, against which it's targeted, and it could be a once every six-month dose. This is a really exciting space, especially with the approval of asundexian recently in secondary stroke prevention. As you know, anticoagulants are almost a $20 billion category.
What we have here is the promise of anticoagulation without bleeding risk, which is sort of the holy grail, right? Because you're targeting Factor XI, unlike Factor Xa, you don't hit both pathways. You only hit the intrinsic pathway, not the extrinsic pathway. Overall, we're very excited about this program. We just concluded enrollment on a large phase II, over 400 patients, and we hope to have top-line data by the end of the year. What we hope to see there is that by targeting Factor XI, you get a greater reduction in VTE events post total knee arthroplasty. This is sort of an artificial setting to do a phase II because you have a higher rate of VTEs post total knee arthroplasty, but it actually reads really well into other VTE indications, such as secondary stroke prevention, even primary stroke prevention. So very excited overall.
Got it. What more can you say about the data lock and disclosure process and coordination with Sirius?
Yeah, I could say that it is all proceeding along schedule, so we are on track to have a data share by the end of the year. I think a couple of points of key differentiation, I think, for this mechanism. One thing to add is that when you are doing a knee replacement, as Sam mentioned, the risk of clot really is in the week after a knee replacement, and then it goes away when patients get mobile. What you are really doing is testing that. What we do is we actually give the drug several weeks in advance to get them therapeutic at that day. What we are anticipating that despite that, the promise of Factor XI, there shouldn't be any increase in bleeding, even though the patients are having major surgery.
That is what we anticipate should be the outcome, and then to see good reduction on par with the other mechanisms. The other differentiating factors for an siRNA, of course, one is, as Sam mentioned, the infrequent dosing. Another area where compliance with medicine is a huge issue, if you had something that was just dosed every six months, it could just be done in office and patients don't have to worry about it the rest of the time. Very promising to make sure patients stay anticoagulated, because even missing a few doses can put patients at risk for stroke and other things. The other thing is, although it is infrequent dosing, the drug is actually much more reversible than, say, especially a biologic, because there is no circulating inhibitor to Factor XI.
If a patient did have a fall on our drug or needed to have elective surgery, they could just get FFP Factor XI replacement and reverse the effect, which is a big differentiator versus, say, the antibody or even oral, where you have an inhibitor. Even if you gave Factor XI, it is not really going to work until the drug is actually cleared.
Yeah. Makes sense.
Yeah.
Bristol's going to have data updates with milvexian by the end of this year, and AFib data first quarter next year. How's that going to inform your development path? Strategically, talk about how you would run the phase III studies. Would you potentially partner those out or do them on your own?
Yeah. I'll take the second question first, which is, given our balance sheet, strength of our balance sheet, we're able to do all these trials ourselves, right? I think that's the great advantage we have as a company, that we can advance multiple phase IIIs next year. In terms of the different data sets, I think we're keenly watching LIBREXIA for milvexian in secondary stroke. If that is positive, that means there's two phase IIIs that are positive and gives the category a lot greater probability of success. In fact, if those small molecules work, where the aPTT doesn't go up as very high compared to an siRNA, it's almost, I wouldn't say a guarantee, but it increases the likelihood quite a bit that siRNA would work with the convenience of once every six-month dosing. I think the secondary stroke prevention market data we're watching keenly.
I think for other opportunities, there's the LIBREXIA all-comer trial in AFib, and if that's positive, this category is going to triple in size, essentially. But also, another market to look at, trial to look at is the LILAC trial, which is going to read out next year from Novartis, and that's for the DOAC-ineligible AFib population, and that's an equally large population. Almost 30% of people with AFib are ineligible for DOACs. So, I think a lot more to come on which indications we develop and how we want to navigate different phase IIIs. But at this point, we're focused on getting the phase II data out, but at the same time, we're doing everything we can on CMC and other aspects to gear up for phase IIIs.
Makes sense. I want to ask on CASGEVY. How should we think about fourth quarter and 2027? With Beam potentially filing as early as the end of this year, what worries you the most about the competitive landscape?
Yeah, I think we are very pleased with the momentum on CASGEVY and the demand building up there. You saw that we hit close to a $100 million revenue run rate in the last quarter. Vertex did mention some seasonality, there may be a little change there, but overall, the trajectory looks really good for how CASGEVY is going to continue to grow and become that multi-billion dollar drug. I think at this point, we have so much data, so much more than any other competitor, and we have such an established infrastructure and network of all the centers that are doing it, both U.S. and ex-U.S. It is going to be hard to dislodge CASGEVY as sort of the leading drug for sickle cell patients and thalassemia patients.
We are pretty much out of time, so maybe just to close out, if you want to highlight your cash position and key catalysts ahead investors should be focused on.
Yeah. From a balance sheet perspective, we have over $2 billion. We have, as I said, a number of programs moving forward, but from a data standpoint, our phase II data for siRNA is something that people are watching keenly. But continuing data from both CTX310 and zugo-cel, but also potentially early data next year from CTX340 in refractory hypertension and A1AT make it a very catalyst-rich year.
Great. Thanks so much, Sam, Naimish. Thanks for joining us.
Thank you.